Global Influenza Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: pbi
Veröffentlicht am: 11.03.2018 14:53
Rubrik: Umwelt & Energie

(Presseportal openBroadcast) - Influenza is commonly known as “flu” or “seasonal flu” caused by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. Influenza mainly affected by three type’s influenza virus, called type A, type B and type C. Influenza virus generally spread through the air by coughing and sneezing or touching contaminated surfaces by a virus. Influenza can be diagnosed by testing throat, sputum and nose. Numbers of rapid tests are available for detecting influenza virus. Influenza can be treated with antiviral drugs or prevented by administering influenza vaccine and several other fluid management methods. Influenza virus spreads around the world in yearly outbreaks that result in millions of severe illness and thousands of deaths across the world. WHO every year predicts few strains which are expected to circulate in following year, that allows pharmaceutical companies to develop influenza vaccine against these stains.

Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth influenza vaccine market.

Influenza Vaccines market has been segmented on the basis of vaccine type, strain type, formulation type, end user, and region

A sample of this report is available upon request @

Based on vaccine type, Influenza Vaccines market segmented as follows:
• Killed or Inactivated Vaccine
• Live Vaccine

Based on strain type, Influenza Vaccines market segmented as follows:
• Trivalent Influenza Vaccine
• Quadrivaleant Influenza Vaccine

Based on formulation type, Influenza Vaccines market segmented as follows:
• Injections
• Nasal Sprays

Based on distribution channel, Influenza Vaccines market segmented as follows:
• Government Immunization programmes
• Non Governmental Organizations (NGOs)
• Hospitals
• Clinics

To view TOC of this report is available upon request @

Players in influenza vaccine market focusing on developing effective vaccine i.e.quadrivalent against influenza virus and eyeing on expanding geographic presence to increase the market revenue for influenza vaccine products. For Instance in June 2016, Sanofi received a positive end of procedure from the German which helps in getting market authorization for VaxigripTetra, a quadrivalent vaccine against influenza. Several leading players in influenza vaccine market shipping the vaccine to U.S. market to meet seasonal demand in the country. Securing government tenders has become essential for influenza vaccine manufacturers to gain larger market share and helps in sustaining the business. For instance in 2015, Sinovac Biotech Ltd. received tender award from Beijing government to supply seasonal influenza vaccine.

Need more information about this report @

Influenza Vaccines market has been segmented into five regions Viz. North Americas, Europe, Asia Pacific, Latin America and Middle East and Africa. Each year, there are two seasons of influenza because of northern and southern hemispheres have winter in different times. Occurrence of influenza infections high in developing countries than developed counters which makes the market lucrative for players in developing countries. However, Influenza vaccine market in North America expected to witness significant growth owing U.S.’s yearly vaccination programme. In Europe influenza vaccine limited to the high risk groups rather than blanket vaccination programmes which market to grow at moderate growth rate. Asia Pacific market expected to grow at significant CAGR owing to increasing affordability, larger and subsidized immunization programs in several countries in the Asia region.

Some of the players in the influenza vaccines market include GlaxoSmithKline plc., Seqirus (CSL Limited), AstraZeneca, Sanofi Pasteur Inc., Sinovac Biotech Ltd., Novavax, Inc., DAIICHI SANKYO COMPANY, LIMITED., Mitsubishi Tanabe Pharma., Protein Sciences Corporation to name a few. There are several influenza vaccine candidates in late stage clinical pipeline which are expected hit the market in forecast period. For instance, in 2017 Daiichi Sankyo’s VN-100 and MEDI3250 influenza vaccine expected to get market approval in Japan.

Get access to full summary @



Toll Free (US): +1-866-598-1553
Website @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.